DrugCombination product
Budigalimab clinical trials
Also written ABBV-181.
Keep track of what changes. Save the budigalimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
- ABBV-181
- 17
Studies by the year they started
21 studies that test it; most in 2024 (5)
| Year | Studies |
|---|---|
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 0
Often tested with
Tested in the same studies.
Livmoniplimab (6) · Paclitaxel (3) · Gemcitabine (3) · Pembrolizumab (2) · Revdofilimab (2) · Docetaxel (2) · Eltivutabart (2) · Albumin-Bound Paclitaxel (2)
Studies
Open first, then newest update. How each study uses budigalimab is read from its arms, and is right about nine times in ten.
Testing it · 21
- A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous TumorsRecruitingPhase 1AbbVieNCT07241039Written as Budigalimab
- Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanRecruitingPhase 1AbbVieNCT05005403Written as Budigalimab
- A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)TerminatedPhase 1AbbVieNCT06487559Written as Budigalimab
- Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2/3AbbVieNCT06236438Written as Budigalimab
- A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingPhase 2/3AbbVieNCT06109272Written as Budigalimab
- A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1AbbVieNCT03893955Written as ABBV-181
- Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC PatientsCompletedPhase 2Trishula Therapeutics, Inc.NCT06119217Written as TTX-030, budigalimab, nab-paclitaxel and gemcitabine
- Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid TumorsActive, not recruitingPhase 1AbbVieNCT05599984Written as Budigalimab
- A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid TumorsActive, not recruitingPhase 1AbbVieNCT02988960Written as ABBV-181
- A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382TerminatedPhase 2AbbVieNCT06032546Written as Budigalimab
- A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid TumorsTerminatedPhase 1AbbVieNCT06158958Written as Budigalimab
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingPhase 2AbbVieNCT05822752Written as Budigalimab
- Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)Active, not recruitingPhase 2AbbVieNCT06632951Written as Budigalimab
- TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced CancersCompletedPhase 1Trishula Therapeutics, Inc.NCT04306900Written as TTX-030, budigalimab and mFOLFOX6
- Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1AbbVieNCT03821935Written as Budigalimab
- A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung CancerCompletedPhase 1AbbVieNCT03639194Written as Budigalimab
- A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1CompletedPhase 1AbbVieNCT04223804Written as ABBV-181
- Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)CompletedPhase 1AbbVieNCT04799353Written as Budigalimab
- A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell CarcinomaTerminatedPhase 1AbbVieNCT03818542Written as ABBV-181
- A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal CancerTerminatedPhase 1AbbVieNCT03035279Written as ABBV-181
See all 21 studies that test budigalimab →
Given in every arm · 7 — budigalimab is usual care beside what is tested
- Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsRecruitingPhase 1/2AbbVieNCT06772623Written as Budigalimab
- A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaActive, not recruitingPhase 2AbbVieNCT06628310Written as Budigalimab
- Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer MetastasisTerminatedPhase 1AbbVieNCT04807972Written as Budiglimab
- A Study of ABT-165 in Subjects With Solid TumorsCompletedPhase 1AbbVieNCT01946074Written as ABBV-181
- A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedPhase 1AbbVieNCT04196283Written as ABBV-181
- A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1AbbVieNCT03071757Written as ABBV-181
- A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid TumorsCompletedPhase 1AbbVieNCT03000257Written as ABBV-181
Codes
What other systems call budigalimab · ClinicalTrials.gg INT001732
- MeSH (NLM) C000719868budigalimabOne source ClinicalTrials.gov
- UNII (FDA) 6VDO4TY3OOBUDIGALIMABOne source FDA
- NCI Thesaurus C137682BudigalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719868 | budigalimab | One source ClinicalTrials.gov |
| UNII (FDA) | 6VDO4TY3OO | BUDIGALIMAB | One source FDA |
| NCI Thesaurus | C137682 | Budigalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.